Sergio Iannazzo

Turin, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.

Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.

Journal: Advances in therapy
Published: February 26, 2024

Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities.

Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities.

Journal: Advances in therapy
Published: November 02, 2022

Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.

Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.

Journal: Future oncology (London, England)
Published: February 04, 2022

A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen.

A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen.

Journal: Global & regional health technology assessment
Published: October 23, 2020

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.

Journal: BMC cancer
Published: October 09, 2020

Cost-analysis of persistent hyperkalaemia in non-dialysis chronic kidney disease patients under nephrology care in Italy.

Cost-analysis of persistent hyperkalaemia in non-dialysis chronic kidney disease patients under nephrology care in Italy.

Journal: International journal of clinical practice
Published: October 30, 2019

Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.

Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.

Journal: Applied health economics and health policy
Published: June 07, 2019

Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.

Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.

Journal: Alimentary pharmacology & therapeutics
Published: October 23, 2018

Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.

Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.

Journal: Current medical research and opinion
Published: August 09, 2018

A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.

A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.

Journal: PharmacoEconomics
Published: February 03, 2018

Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.

Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.

Journal: PharmacoEconomics
Published: October 17, 2017

Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.

Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.

Journal: Journal of medical economics
Published: August 15, 2017
Showing 1-12 of 26

Last Updated: 09/26/2026